Biogen启动Omaveloxolone治疗弗里德赖希共济失调的儿科III期研究

药事纵横
19 Jun

2025年6月18日,Biogen公司宣布启动全球III期临床试验BRAVE研究的给药工作。该研究旨在评估Omaveloxolone对2至16岁以下弗里德赖希共济失调(FA)患儿的疗效和安全性。无论是否具备行走能力,患者均可能符合入组条件。受试者将以2:1的比例随机分配,每日接受一次Omaveloxolone或安慰剂治疗52周,随后可转入开放标签扩展期(OLE)。目前,Omaveloxolone以...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10